|
14.03.2005 13:02:00
|
Inamed and Rightfield Solutions to Offer Web-Based Patient Education P
Inamed and Rightfield Solutions to Offer Web-Based Patient Education Program for Patients Using Breast Aesthetic and Lap-Band System Products System Designed to Improve Patient Education Through Technology; Program Combines Clinical and Legal Best Practices Education
Rightfield Solutions, LLC, developers of Emmi(TM), Expectation Management and Medical Information, and Inamed Corporation (NASDAQ:IMDC), a global healthcare company with more than 25 years of experience developing, manufacturing, and marketing innovative, high-quality, science-based products, announced today that the two companies will join forces to help hospitals, medical groups and physicians ensure that patients considering either breast or obesity surgery are more fully educated and informed about their medical procedures.
Emmi is an expectation management, patient satisfaction and risk reduction tool that combines clinical and legal best practices with an easy-to-understand web-based program that explains to patients what to expect before, during and after surgical procedures. This information is particularly important to patients who are considering breast augmentation or weight loss surgery as the program clearly explains the procedure, its risks, benefits and impact on their lives.
The Emmi relationship with Inamed positions this patient offering in the area of breast and obesity surgery as an industry first, focused on improving patient education and safety. With this agreement, Inamed becomes one of the first medical device manufacturers in the world to add web-based, patient friendly educational materials for its physician customers to offer their patients.
The Centers for Medicaid and Medicare Services (CMS) and the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) have initiated programs to improve patient education and safety with the help of technology-based solutions.
"The technology-based tool is an important offering to patients as it explains in easy-to-understand terms what to expect before, during and after surgical procedures," said Nick Teti, Chairman, President and CEO of Inamed. "We believe that giving patients an additional educational tool that can be used in the comfort of their own home or their physician's office will help lead to greater satisfaction, better outcomes and will reduce the level of erroneous expectations."
In addition to Emmi programs for breast surgery and weight reduction procedures, there are Emmi programs for orthopedic, obstetric/gynecology, LASIK and several other medical procedures. All Emmi programs are developed by board-certified physicians in their respective fields. Emmi not only explains pre-surgical procedures and the operation itself, but also what will happen afterward. For example, many women who have had breast augmentation report that they did not fully understand what to expect after their procedure. Such misunderstandings lead to poorer outcomes and lower patient satisfaction, as well as increased risk of litigation for physicians and insurers.
Emmi also helps physicians as it supports the informed consent process and provides basic information to patients so that physicians and office staff can spend more time during office visits discussing specific concerns and building better relationships with their patients. This translates into time and financial savings as physicians don't have to use their time or staff time to answer basic questions and can help with the recovery process. In addition, use of Emmi differentiates physicians and may help convert patients from "browsers to buyers."
"Inamed's leadership is setting a new standard for the medical device industry," said Jordan Dolin, CEO of Rightfield Solutions. "By offering Emmi, Inamed has taken a pioneering and decisive step, which will ultimately benefit not only their physician and hospital clients, but most importantly, make a real difference in the lives of patients undergoing medical procedures that use their products."
About Rightfield Solutions and Emmi
Emmi(TM), Expectation Management and Medical Information, is a powerful risk management and patient satisfaction tool developed by Chicago-based Rightfield Solutions, LLC. Emmi combines clinical and legal best practices into a web-based interactive tool for healthcare providers who want to manage risk by developing better relationships with patients and by increasing their satisfaction with the care provided. Introduced in 2002, Emmi has been provided to over 25,000 patients to date. Additionally, 400 surgeons and a growing number of leading healthcare industry associations, and malpractice insurance carriers are using or endorsing the product. There are currently Emmi programs covering a wide range of surgical and medical procedures including General Surgery (such as Hernia), Bariatric (Gastric By-Pass), Oral Surgery, Plastic/Cosmetic Surgery as well as Orthopedic, Obstetrics/Gynecology and LASIK procedures. All Emmi programs are developed by board certified physicians within their respective fields. For additional information on Emmi please visit www.rightfield.net or contact Jordan Dolin at 312-236-3650, ext. 14. For an Emmi demo please visit www.emmidemo.com .
About Inamed Corporation
Inamed (Nasdaq:IMDC) is a global healthcare company with over 25 years of experience developing, manufacturing and marketing innovative, high-quality, science-based products. Current products include breast implants for aesthetic augmentation and for reconstructive surgery; a range of dermal products to treat facial wrinkles; and minimally invasive devices for obesity intervention, including the LAP-BAND(R) System for morbid obesity. The Company's website is www.inamed.com .
Forward-Looking Statements
This press release contains, in addition to historical information, forward-looking statements. Such statements are based on management's current estimates and expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Inamed is providing this information as of March 14, 2005, and expressly disclaims any duty to update information contained in this press release.
Forward-looking statements in this press release include, without limitation, express and implied statements regarding Inamed's anticipated sales, operating results, expenses, product development, and regulatory approval. These forward-looking statements involve risks and uncertainties which could cause actual results to differ materially from those expressed or implied here. Readers are referred to the documents filed by Inamed with the Securities and Exchange Commission, specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements, including but not limited to: exposure to product liability and intellectual property claims; exposure to liabilities that may not be adequately covered by insurance or for which there is no insurance; potential negative publicity concerning product safety; potential fluctuations in quarterly and annual results; the effect of changing accounting and public reporting rules and regulations; volatility of Inamed's stock price; changes in the economy and consumer spending; competition from existing and/or new products; failure or delay of clinical trials; uncertainty in receiving timely regulatory approval or market acceptance for new products; dependence on a single supplier for each of Inamed's silicone raw materials, bovine and human collagen-based products and hyaluronic acid-based products; failure to protect Inamed's intellectual property; adverse changes in the regulatory or legislative environment (both in the U.S. and internationally) affecting our businesses; and failure of our collaborative partners to perform. The information contained in this press release is a statement of Inamed's present intention, belief or expectation and is based upon, among other things, the existing regulatory environment, industry conditions, market conditions and prices, the economy in general and Inamed's assumptions. Inamed may change its intention, belief or expectation, at any time and without notice, based upon any changes in such factors, in Inamed's assumptions or otherwise. Inamed undertakes no obligation to review or confirm analysts' expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
By including any information in this press release, Inamed does not necessarily acknowledge that disclosure of such information is required by applicable law or that the information is material.
--30--WAM/la*
Business Editors/Health/Medical Writers
CHICAGO & SANTA BARBARA, Calif.--(BUSINESS WIRE)--March 14, 2005--
Rightfield Solutions, LLC, developers of Emmi(TM), Expectation Management and Medical Information, and Inamed Corporation (NASDAQ:IMDC), a global healthcare company with more than 25 years of experience developing, manufacturing, and marketing innovative, high-quality, science-based products, announced today that the two companies will join forces to help hospitals, medical groups and physicians ensure that patients considering either breast or obesity surgery are more fully educated and informed about their medical procedures.
Emmi is an expectation management, patient satisfaction and risk reduction tool that combines clinical and legal best practices with an easy-to-understand web-based program that explains to patients what to expect before, during and after surgical procedures. This information is particularly important to patients who are considering breast augmentation or weight loss surgery as the program clearly explains the procedure, its risks, benefits and impact on their lives.
The Emmi relationship with Inamed positions this patient offering in the area of breast and obesity surgery as an industry first, focused on improving patient education and safety. With this agreement, Inamed becomes one of the first medical device manufacturers in the world to add web-based, patient friendly educational materials for its physician customers to offer their patients.
The Centers for Medicaid and Medicare Services (CMS) and the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) have initiated programs to improve patient education and safety with the help of technology-based solutions.
"The technology-based tool is an important offering to patients as it explains in easy-to-understand terms what to expect before, during and after surgical procedures," said Nick Teti, Chairman, President and CEO of Inamed. "We believe that giving patients an additional educational tool that can be used in the comfort of their own home or their physician's office will help lead to greater satisfaction, better outcomes and will reduce the level of erroneous expectations."
In addition to Emmi programs for breast surgery and weight reduction procedures, there are Emmi programs for orthopedic, obstetric/gynecology, LASIK and several other medical procedures. All Emmi programs are developed by board-certified physicians in their respective fields. Emmi not only explains pre-surgical procedures and the operation itself, but also what will happen afterward. For example, many women who have had breast augmentation report that they did not fully understand what to expect after their procedure. Such misunderstandings lead to poorer outcomes and lower patient satisfaction, as well as increased risk of litigation for physicians and insurers.
Emmi also helps physicians as it supports the informed consent process and provides basic information to patients so that physicians and office staff can spend more time during office visits discussing specific concerns and building better relationships with their patients. This translates into time and financial savings as physicians don't have to use their time or staff time to answer basic questions and can help with the recovery process. In addition, use of Emmi differentiates physicians and may help convert patients from "browsers to buyers."
"Inamed's leadership is setting a new standard for the medical device industry," said Jordan Dolin, CEO of Rightfield Solutions. "By offering Emmi, Inamed has taken a pioneering and decisive step, which will ultimately benefit not only their physician and hospital clients, but most importantly, make a real difference in the lives of patients undergoing medical procedures that use their products."
About Rightfield Solutions and Emmi
Emmi(TM), Expectation Management and Medical Information, is a powerful risk management and patient satisfaction tool developed by Chicago-based Rightfield Solutions, LLC. Emmi combines clinical and legal best practices into a web-based interactive tool for healthcare providers who want to manage risk by developing better relationships with patients and by increasing their satisfaction with the care provided. Introduced in 2002, Emmi has been provided to over 25,000 patients to date. Additionally, 400 surgeons and a growing number of leading healthcare industry associations, and malpractice insurance carriers are using or endorsing the product. There are currently Emmi programs covering a wide range of surgical and medical procedures including General Surgery (such as Hernia), Bariatric (Gastric By-Pass), Oral Surgery, Plastic/Cosmetic Surgery as well as Orthopedic, Obstetrics/Gynecology and LASIK procedures. All Emmi programs are developed by board certified physicians within their respective fields. For additional information on Emmi please visit www.rightfield.net or contact Jordan Dolin at 312-236-3650, ext. 14. For an Emmi demo please visit www.emmidemo.com .
About Inamed Corporation
Inamed (Nasdaq:IMDC) is a global healthcare company with over 25 years of experience developing, manufacturing and marketing innovative, high-quality, science-based products. Current products include breast implants for aesthetic augmentation and for reconstructive surgery; a range of dermal products to treat facial wrinkles; and minimally invasive devices for obesity intervention, including the LAP-BAND(R) System for morbid obesity. The Company's website is www.inamed.com .
Forward-Looking Statements
This press release contains, in addition to historical information, forward-looking statements. Such statements are based on management's current estimates and expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Inamed is providing this information as of March 14, 2005, and expressly disclaims any duty to update information contained in this press release.
Forward-looking statements in this press release include, without limitation, express and implied statements regarding Inamed's anticipated sales, operating results, expenses, product development, and regulatory approval. These forward-looking statements involve risks and uncertainties which could cause actual results to differ materially from those expressed or implied here. Readers are referred to the documents filed by Inamed with the Securities and Exchange Commission, specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements, including but not limited to: exposure to product liability and intellectual property claims; exposure to liabilities that may not be adequately covered by insurance or for which there is no insurance; potential negative publicity concerning product safety; potential fluctuations in quarterly and annual results; the effect of changing accounting and public reporting rules and regulations; volatility of Inamed's stock price; changes in the economy and consumer spending; competition from existing and/or new products; failure or delay of clinical trials; uncertainty in receiving timely regulatory approval or market acceptance for new products; dependence on a single supplier for each of Inamed's silicone raw materials, bovine and human collagen-based products and hyaluronic acid-based products; failure to protect Inamed's intellectual property; adverse changes in the regulatory or legislative environment (both in the U.S. and internationally) affecting our businesses; and failure of our collaborative partners to perform. The information contained in this press release is a statement of Inamed's present intention, belief or expectation and is based upon, among other things, the existing regulatory environment, industry conditions, market conditions and prices, the economy in general and Inamed's assumptions. Inamed may change its intention, belief or expectation, at any time and without notice, based upon any changes in such factors, in Inamed's assumptions or otherwise. Inamed undertakes no obligation to review or confirm analysts' expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
By including any information in this press release, Inamed does not necessarily acknowledge that disclosure of such information is required by applicable law or that the information is material.
--30--WAM/la*
CONTACT: Scott Public Relations for Rightfield Solutions Brenna Harrington, 800-396-8470 Brenna.scottpr@mac.com or Inamed Corporation Dan Cohen, 202-638-4179
KEYWORD: ILLINOIS CALIFORNIA INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL DEVICES CONSUMER/HOUSEHOLD MEDICAL BANKING PRODUCT MARKETING AGREEMENTS SOURCE: Rightfield Solutions, LLC
Copyright Business Wire 2005
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu INAMED Corp.mehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu INAMED Corp.mehr Analysen
Indizes in diesem Artikel
| NASDAQ Comp. | 19 161,63 | -1,63% | |
| S&P 600 SmallCap | 935,46 | -0,94% |
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.